Eli Lilly and Company
LLYPharmaceuticals
$1,417.54+3.19%As of Oct 30vs prior close
- Market cap
- $1.3T
- P/E (TTM)
- 61.6×
- P/E (FY1)
- 41.1×
- From 52W high
- 0.00%
- EPS (LTM)
- $22.95
- Revenue (LTM)
- $65.2B
- Net margin
- 31.67%
- Dividend yield
- 0.47%
Nomior Score
72
Vanguard CompounderTop 7% of the scored universe
Growth78
Quality82
Value34
Momentum75
Resilience50
Growth
+13.28%revenue a year over 9 fiscal years
FY16 $21.2BLTM $65.2B
Connections
Revenue to profitQ3 FY26
26% of revenue became net profit, down 5 pts on a year.
Latest resultsthird-quarter 2026
- Net income
- $6.5 billion
Lilly reported strong third-quarter sales growth led by Mounjaro and Zepbound, with volume gains outweighing lower realized prices. Profit rose, but was reduced by a large charge for acquired in-process research and development tied to recent acquisitions. The company raised its full-year revenue outlook, while its full-year earnings guidance was lowered slightly after the acquisition charges.
Who owns it
6funds, 9 tracked portfolios